207 related articles for article (PubMed ID: 37707764)
1. Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.
Thaçi D; Tziotzios C; Ito T; Ko J; Karadağ AS; Fang H; Edwards RA; Bonfanti G; Wolk R; Tran H; Law E
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2621-2634. PubMed ID: 37707764
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
[TBL] [Abstract][Full Text] [Related]
3. A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Immunotherapy; 2023 Oct; 15(14):1093-1103. PubMed ID: 37403610
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Lancet; 2023 May; 401(10387):1518-1529. PubMed ID: 37062298
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.
Winnette R; Banerjee A; Sikirica V; Peeva E; Wyrwich K
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):602-609. PubMed ID: 35000236
[TBL] [Abstract][Full Text] [Related]
6. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
7. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Zhu L; Zhu H; Cox LA; Vincent MS; Sinclair R
JID Innov; 2022 Nov; 2(6):100156. PubMed ID: 36277481
[TBL] [Abstract][Full Text] [Related]
9. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
12. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
14. LITFULO
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2023; 21(6):434-438. PubMed ID: 38051245
[TBL] [Abstract][Full Text] [Related]
15. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
Senna MM; Kwon O; Piraccini BM; Sinclair R; Ball S; Ding Y; Chen YF; Dutronc Y; King B
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3209-3220. PubMed ID: 37991697
[TBL] [Abstract][Full Text] [Related]
16. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
Br J Dermatol; 2020 Oct; 183(4):702-709. PubMed ID: 31970750
[TBL] [Abstract][Full Text] [Related]
17. Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan.
Macey J; Kitchen H; Aldhouse NVJ; Burge RT; Edson-Heredia E; McCollam JS; Isaka Y; Torisu-Itakura H
Dermatol Ther (Heidelb); 2021 Apr; 11(2):433-447. PubMed ID: 33464474
[TBL] [Abstract][Full Text] [Related]
18. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
Piraccini BM; Ohyama M; Craiglow B; Bewley A; Ding Y; Chen YF; Dutronc Y; Pierce E; Durand F; Mostaghimi A
J Dermatolog Treat; 2023 Dec; 34(1):2227299. PubMed ID: 37381691
[TBL] [Abstract][Full Text] [Related]
19. A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
Macey J; Kitchen H; Aldhouse NVJ; Edson-Heredia E; Burge R; Prakash A; King BA; Mesinkovska N
Br J Dermatol; 2022 May; 186(5):849-860. PubMed ID: 34811721
[TBL] [Abstract][Full Text] [Related]
20. The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial.
Rafati M; Mahmoudian R; Golpour M; Kazeminejad A; Saeedi M; Nekoukar Z
Dermatol Ther; 2022 Jun; 35(6):e15450. PubMed ID: 35289043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]